Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells

Cancer Letters

Volumn 259, Issue 2, 2008, Pages 156-164

  Fortunati, Nicoletta ^a   Bertino, Silvia ^a   Costantino, Lucia ^b   Bosco, Ornella ^b   Vercellinatto, Ilenia ^b   Catalano, Maria Graziella ^b   Boccuzzi, Giuseppe ^a,b  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Apoptosis; Breast cancer; Cell cycle; Valproic acid

Indexed keywords

ESTROGEN; HISTONE DEACETYLASE INHIBITOR; PROTEIN BAK; PROTEIN BCL 2; PROTEIN P21; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL STRAIN MCF 7; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BREAST NEOPLASMS; CASPASE 8; CASPASE 9; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ESTROGENS; FEMALE; HISTONE DEACETYLASES; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; VALPROIC ACID;

EID: 37049031651     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.10.006     Document Type: Article

References (34)

1. Clarke R., Leonessa F., and Trock B. Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. Semin. Oncol. 32 (2005) S9-S15
2. Evan G.I., and Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 411 (2001) 245-248
3. Greenlee R.T., Murray T., Bolden S., and Wingo P.A. Cancer statistics 2000. CA Cancer J. Clin. 50 (2000) 7-33
4. Johnstone R.W., and Licht J.D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?. Cancer Cell 4 (2003) 13-18
5. Jenuwein T., and Alli's C.D. Translating the histone code. Science 293 (2001) 1074-1080
6. Davie J.R., and Moniwa M. Control of chromatin remodelling. Crit. Rev. Eukaryotic Gene Expression 10 (2000) 303-325
7. Schmidt K., Gust R., and Jung M. Inhibitors of histone deacetylase suppress the growth of MCF-7 breast cancer cells. Arch. Pharm. 332 (1999) 353-357
8. Davis T., Kennedy C., Chiew Y.-E., Clarke C.L., and DeFazio A. Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin. Cancer Res. 6 (2000) 4334-4342
9. Vigushin D.M., Ali A., Pace P.E., Mirsaidi N., Ito K., Adcock I., and Coombes R.C. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res. 7 (2001) 971-976
10. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., and Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276 (2001) 36734-36741
11. Olsen C.M., Meussen-Elholm E.T.M., Roste L.S., and Tauboll E. Antiepileptic drugs inhibit cell growth in the human breast cancer cell line MCF-7. Mol. Cell Endocrinol. 213 (2004) 173-179
12. Hodges-Gallagher L., Valentine C.D., Bader S.E., and Kushner P.J. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res. Treat. 105 (2007) 297-309
13. Perez-Pinzon M.A., Xu G.P., Born J., Lorenzo J., Busto R., Rosenthal M., and Sick T.J. Cytochrome C is released from mitochondria into the cytosol after cerebral anoxia or ischemia. J. Cer. Blood Flow Met. 19 (1999) 39-43
14. Ravindranath V. Animal models and molecular markers for cerebral ischemia- reperfusion injury in brain. Methods Enzymol. 233 (1994) 610-619
15. Zoccarato F., Valente M., and Alexandre A. Identification of an NADH plus iron dependent, Ca2+ activated hydrogen peroxide production in synaptosomes. Biochim. Biophys. Acta 1176 (1993) 208-214
16. Chomczynski P., and Sacchi N. Single step method of RNA isolation by guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162 (1987) 156-159
17. DeVane C.L. Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol. Bull. 37 (2003) 25-42
18. Henderson C., and Brancolini C. Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug-resistant phenotype. Drug Res. Update 6 (2003) 247-256
19. Marks P.A., Richon V.M., Bresolw R., and Rifkind R.A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13 (2001) 477-483
20. Vigushin D.M., and Coombes R.C. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13 (2002) 1-13
21. Munster P.N., Troso-Sandoval T., Rosen N., Rifkind R., Marks P.A., and Richon V.M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 61 (2001) 8492-8497
22. Richon V.M., Sandhoff T.W., Rifkind R.A., and Marks P.A. Histone deacetylase inhibitors selectively induce p21WAF expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 97 (2000) 10014-10019
23. Sambucetti L.C., Fisher D.D., Zabludoff S., Known P.O., Chamberlin H., Trogani N., Xu H., and Cohen D. Histone deacetylase inhibition selectively alters the activity and expression of the cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem. 274 (1999) 34940-34947
24. Saito A., Yamashita T., Makiro Y., Nosaka Y., Tsuchiya K., Ando T., Suzuki T., Tsuruo T., and Nakanishi O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vitro antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA 96 (1999) 4592-4597
25. Schmitt C.A., and Lowe S.W. Apoptosis is critical for drug response in vivo. Drug. Resist. Updat. 4 (2001) 132-134
26. Henderson C., Mizzau M., Paroni G., Maestro R., Schneider C., and Brancolini C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors Trichostatin-A (TSA) and Suberoylanilide Hidroxamic Acid (SAHA). J. Biol. Chem. 278 (2003) 12579-12589
27. Ruefli A.A., Ausserlechner M.J., Bernhard D., Sutton V.R., Tainton K.M., Kofler R., Smyth M.J., and Johnstone R.W. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl. Acad. Sci. USA 98 (2001) 10833-10838
28. Ricci J.E., Gottlieb R.A., and Green D.R. Caspase-mediated loss of mitochondrial function and generation of reactive oxygen species during apoptosis. J. Cell Biol. 160 (2003) 65-75
29. Paroni G., Henderson C., Schneider C., and Brancolini C. Caspase-2-induced apoptosis is dependent on caspase-9, but its processing during UV- or tumor necrosis factor-dependent cell death requires caspase-3. J. Biol. Chem. 276 (2001) 21907-21915
30. Sheikh M.S., Garcia M., Zhan Q., Liu Y., and Fornace A.J. Cell cycle independent regulation of p21Waf1/Cip1 and retinoblastoma protein during okadaic acid-induced apoptosis is coupled with induction of Bax protein in human breast carcinoma cells. Cell Growth Differ. 7 (1996) 1599-1607
31. Margueron R., Licznar A., Lazennec G., Vignon F., and Cavaillès V. Oestrogen receptor alpha increases p21(WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells. J. Endocrinol. 179 (2003) 41-53
32. Ishikawa K., Ishii H., and Saito T. DNA damage-dependent cell cycle checkpoints and genomic stability. DNA Cell Biol. 25 (2006) 406-411
33. Fortunati N., Catalano M.G., Arena K., Brignardello E., Piovesan A., and Boccuzzi G. Valproic acid induces the expression of the Na symporter and iodine uptake in poorly differentiated thyroid cancer cells. J. Clin. Endocrinol. Metab. 89 (2004) 1006-1009
34. Catalano M.G., Fortunati N., Pugliese M., Costantino L., Poli R., Bosco O., and Boccuzzi G. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J. Clin. Endocrinol. Metab. 90 (2005) 383-1389